More new drugs for HIV and associated infections.
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy; D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077404:Cidofovir; D002986:Clinical Trials as Topic; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy; D003596:Cytosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007546:Isoquinolines / Q000191:economics; D019888:Nelfinavir; D019829:Nevirapine; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D013451:Sulfonic Acids / Q000191:economics
D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D007546:Isoquinolines; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D011480:Protease Inhibitors; D011725:Pyridines; D013451:Sulfonic Acids; D000666:Amphotericin B; D003596:Cytosine; D019829:Nevirapine; D019888:Nelfinavir; D000077404:Cidofovir; D019438:Ritonavir